Eicosapentaenoic Acid as a Bioactive Liquid Lipid in Methotrexate-Loaded Nanostructured Lipid Carriers
Jundishapur Journal of Natural Pharmaceutical Products · 18.07.2026 · 21 (3)
DOI: 10.5812/jjnpp-173185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jundishapur Journal of Natural Pharmaceutical Products, online erschienen am 18.07.2026. Verfasst von Eskandar Moghimipour und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Nanostructured lipid carriers (NLCs) are promising vehicles for the topical delivery of poorly permeable drugs such as methotrexate (MTX). In conventional NLCs, the liquid lipid serves primarily as a structural component, whereas incorporating a bioactive natural liquid lipid may provide additional formulation benefits for the resulting carrier.
Objectives
This study aimed to design and physicochemically characterize MTX-loaded NLCs using eicosapentaenoic acid (EPA), a natural omega-3 fatty acid, as a bioactive liquid lipid, and to identify an optimal formulation through a systematic two-level formulation design.
Methods
Eight formulations were prepared by hot emulsification followed by sonication, with varying amounts of solid lipid (stearic acid), liquid lipid (EPA), and surfactant (soya lecithin). The MTX assay was validated by reversed-phase high-performance liquid chromatography (HPLC) for linearity, limit of detection (LOD), limit of quantification (LOQ), precision, selectivity, and matrix-matched recovery. The formulations were characterized in terms of particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE%), drug loading (DL%), and in vitro release. The release kinetics of the optimal formulation were evaluated using four models (zero-order, first-order, Higuchi, and Korsmeyer-Peppas), and physical stability was monitored for three months.
Results
The HPLC method was linear over 1 - 20 µg/mL (R2 = 0.9981), with LOD and LOQ of 1.56 and 4.72 µg/mL, respectively, and precision of RSD ≤ 2%. Particle size ranged from 88.92 to 160.7 nm, and PDI ranged from 0.252 to 0.405. The optimal formulation (F5; stearic acid 200 mg, EPA 20 mg, lecithin 40 mg) showed a particle size of 88.92 nm, a PDI of 0.284, a zeta potential of ‒18.5 mV, an EE% of 88.40%, and a DL% of 7.89%. Its 24 h cumulative release reached 88.03%; among the tested models, the release best fit the Korsmeyer-Peppas (R2 = 0.987; n = 1.12) and first-order (R2 = 0.977) models, indicating a coupled diffusion–relaxation mechanism. All formulations remained physically stable over three months.
Conclusions
EPA can serve as a bioactive liquid lipid in NLCs, producing nanoscale carriers with high entrapment, adequate drug loading, and sustained release. These findings provide a robust physicochemical basis for topical MTX carriers; however, biological and skin-delivery validation is required before any therapeutic benefit of EPA can be claimed.
Zitieren
APA
Moghimipour, E., Salimi, A., Handali, S., Dayer, D., Malayeri, A., Kaydan, H. H., & Javadiyeh, A. (2026). Eicosapentaenoic Acid as a Bioactive Liquid Lipid in Methotrexate-Loaded Nanostructured Lipid Carriers. Jundishapur Journal of Natural Pharmaceutical Products, 21(3). https://doi.org/10.5812/jjnpp-173185
Vancouver
Moghimipour E, Salimi A, Handali S, Dayer D, Malayeri A, Kaydan HH, et al. Eicosapentaenoic Acid as a Bioactive Liquid Lipid in Methotrexate-Loaded Nanostructured Lipid Carriers. Jundishapur Journal of Natural Pharmaceutical Products. 2026;21(3). doi:10.5812/jjnpp-173185
BibTeX
@article{Moghimipour2026,
author = {Moghimipour, Eskandar and Salimi, Anayatollah and Handali, Somayeh and Dayer, Dian and Malayeri, Alireza and Kaydan, Hossein Heidari and Javadiyeh, Ali},
title = {Eicosapentaenoic Acid as a Bioactive Liquid Lipid in Methotrexate-Loaded Nanostructured Lipid Carriers},
journal = {Jundishapur Journal of Natural Pharmaceutical Products},
year = {2026},
volume = {21},
number = {3},
doi = {10.5812/jjnpp-173185}
}
EUVIMED